EMA Authorised: LysaKare (L-arginine hydrochloride;L-lysine hydrochloride) — Advanced Accelerator Applications

View source ↗

Summary

EMA authorised LysaKare, a medicine containing L-arginine hydrochloride and L-lysine hydrochloride, for the treatment of radiation injuries.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Radiation Injuries

Drugs mentioned

• LysaKare

Snippet

Status: Authorised. Therapeutic area: Radiation Injuries. MAH: Advanced Accelerator Applications. Decision date: 31/03/2026